# MOTS-c mitochondrial aging: The MOTS-c peptide Longevity and Age-Biomarker Research > MOTS-c mitochondrial aging research: how levels change with age, the m.1382A>C longevity variant, aged-mouse performance data, and a dialysis-cohort mortality association. A cited digest. Levels that move with age, a longevity-linked DNA variant, performance restored in old mice, and a human cohort where the peptide tracked mortality risk. ## The gist Here is the MOTS-c mitochondrial aging story in plain terms. As bodies age, the power plants inside cells — the mitochondria — run less smoothly, and the signals they send change too. MOTS-c is one of those signals. Its levels rise and fall with age and fitness, a specific spelling change in mitochondrial DNA that alters MOTS-c has been tied to both longevity and diabetes risk, and in old mice, giving extra MOTS-c restored a surprising amount of physical capacity. In one group of very sick patients, blood MOTS-c even tracked survival. None of this means taking MOTS-c extends human life — it means the molecule is a real part of the aging conversation. ## MOTS-c levels change with age and metabolic state Mitochondrial-derived peptides, including MOTS-c, behave as age-dependent regulators of apoptosis (programmed cell death), insulin sensitivity, and inflammatory markers, and their circulating levels change with age [9]. In healthy aging men, skeletal-muscle MOTS-c expression was higher and correlated with myofiber-type composition, linking the body's own MOTS-c to human muscle aging [15]. The biomarker direction is not uniform. Serum MOTS-c was decreased in obese children and associated with vascular endothelial function [11], while muscle expression rose with age in men [15]. The molecule is mitochondrial-stress-responsive, so its level reflects metabolic context, which is why MOTS-c is studied as a candidate readout of mitochondrial and metabolic health rather than a simple up-or-down-with-age marker [6]. A 2022 review situates it within the broader mitochondrial-derived-peptide family in human aging and age-related disease [6]. ## Are circulating MOTS-c levels a biomarker of health or aging? ### Are circulating MOTS-c levels a biomarker of health or aging? Circulating and tissue MOTS-c change with age and metabolic state, and in a chronic-hemodialysis cohort serum MOTS-c was independently associated with mortality and cardiovascular events, supporting interest in it as a human biomarker [9][12]. In that prospective multicenter cohort of 94 dialysis patients (median 26.5-month follow-up), MOTS-c was independently associated with a composite of all-cause mortality and non-fatal cardiovascular events (Cox HR 1.004, p=0.05) and improved risk-model discrimination (ROC AUC 0.727 to 0.743) [12]. That is among the strongest human clinical-association data for the peptide — and it is an association in a specific patient group, not proof that changing MOTS-c changes outcomes. ## The longevity variant: m.1382A>C A specific mitochondrial DNA polymorphism, m.1382A>C, alters the MOTS-c peptide sequence and has been studied at the intersection of longevity and disease risk. It is pro-diabetogenic in certain populations, linking MOTS-c genetics to type 2 diabetes risk, and is prevalent in some East Asian groups [8]. An earlier commentary raised the hypothesis that MOTS-c genetics may play a role in exceptional human longevity [14]. This is the double edge of the aging story: the same variant that has been explored in the context of long life is associated with diabetes risk in some populations [8][14]. It is also a caution about uniformity — ancestry and genotype appear to shape MOTS-c biology, so findings in one population do not automatically transfer to another [8]. A 2023 diabetes-and-aging review summarizes the human-association and mechanistic data linking MOTS-c to metabolic and aging-related disease [10]. ## Performance restored in aged animals The most striking aging-relevant intervention data come from mice. Exogenous MOTS-c significantly increased treadmill running capacity in aged (22-23.5-month) mice (P=0.000002), along with grip strength and gait, and exercise itself induced endogenous MOTS-c across young, middle-aged, and old animals [2]. The 2024 CK2-binding work helps explain the muscle side: tissue-specific CK2 modulation underlies effects on muscle glucose uptake and atrophy prevention [5]. These are mouse results. They make MOTS-c a serious candidate in aging biology — a [circulating MOTS-c as a biomarker](/mitochondrial-aging) and a possible lever on age-related physical decline — but they are not evidence that supplementing MOTS-c improves healthspan in people, which would require the human trials that have not yet been completed [4]. --- A pixel-clean readout of the MOTS-c record — the AMPK mechanism, the aged-mouse data, and the biomarker thread logged to source and tagged confirmed, every missing human datum flagged in plain HUD caution, with no clinic behind the screen and nothing here dispensed or sold.